Ceftobiprole Activity against over 60,000 Clinical Bacterial Pathogens Isolated in Europe, Turkey, and Israel from 2005 to 2010

Abstract

ABSTRACTCeftobiprole medocaril is a newly approved drug in Europe for the treatment of hospital-acquired pneumonia (HAP) (excluding patients with ventilator-associated pneumonia but including ventilated HAP patients) and community-acquired pneumonia in adults. The aim of this study was to evaluate thein vitroantimicrobial activity of ceftobiprole against prevalent Gram-positive and -negative pathogens isolated in Europe, Turkey, and Israel during 2005 through 2010. A total of 60,084 consecutive, nonduplicate isolates from a wide variety of infections were collected from 33 medical centers. Species identification was confirmed, and all isolates were susceptibility tested using reference broth microdilution methods. Ceftobiprole had high activity against methicillin-susceptibleStaphylococcus aureus(MSSA) (100.0% susceptible), methicillin-susceptible coagulase-negative staphylococci (CoNS), beta-hemolytic streptococci, andStreptococcus pneumoniae(99.3% susceptible), with MIC90values of 0.25, 0.12, ≤0.06, and 0.5 μg/ml, respectively. Ceftobiprole was active against methicillin-resistantS. aureus(MRSA) (98.3% susceptible) and methicillin-resistant CoNS, having a MIC90of 2 μg/ml. Ceftobiprole was active againstEnterococcus faecalis(MIC50/90, 0.5/4 μg/ml) but not against mostEnterococcus faeciumisolates. Ceftobiprole was very potent against the majority ofEnterobacteriaceae(87.3% susceptible), with >80% inhibited at ≤0.12 μg/ml. The potency of ceftobiprole againstPseudomonas aeruginosa(MIC50/90, 2/>8 μg/ml; 64.6% at MIC values of ≤4 μg/ml) was similar to that of ceftazidime (MIC50/90, 2/>16 μg/ml; 75.4% susceptible), but limited activity was observed againstAcinetobacterspp. andStenotrophomonas maltophilia. High activity was also observed against allHaemophilus influenzae(MIC90, ≤0.06 μg/ml) andMoraxella catarrhalis(MIC50/90, ≤0.06/0.25 μg/ml) isolates. Ceftobiprole demonstrated a wide spectrum of antimicrobial activity against this very large longitudinal sample of contemporary pathogens.